On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
Lymphoma Research Foundation Awards More Than $5.4 Million in Lymphoma Research Grants New York, NY…
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab…
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib…
The Importance of Being Seen and Heard In April 2021, Paula Ngon was an active,…
Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF)…
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic…
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either…
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory…